FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1499695412> ?p ?o ?g. }

• W1499695412 abstract "Objective: Compare percent brain volume change (PBVC) between patients with relapsing-remitting multiple sclerosis (RRMS) treated over 6 months with thrice-weekly interferon beta-1a subcutaneously (IFN beta-1a SC) and healthy controls (HCs); analyze correlations between immunological markers and short-term volume changes among treated patients.Background: Chronic RRMS progression is associated with decreased brain volume (atrophy). Over the short term, brain volume may change via inflammation-related hydrodynamic changes, which subside following anti-inflammatory therapy (pseudoatrophy). Responses to such therapy may be influenced by patients’ immunological status before and during treatment.Design/Methods: This 24-week, two-arm (23 RRMS patients receiving IFN beta-1a SC, 15 HCs) pilot study (NCT01085318) evaluated magnetic resonance imaging (MRI) at baseline and 3 and 6 months, and immunological measures at baseline and 6 months. PBVC using SIENA over 0-3, 3-6 and 0-6 months was assessed within groups using Wilcoxon signed-rank test; differences between RRMS patients and HCs were assessed by Wilcoxon rank-sum test. Spearman correlation coefficients were calculated between PBVC and changes in immunological markers in RRMS patients.Results: PBVC between baseline and 3 months was -0.95% (standard deviation, 1.712%) among RRMS patients (p=0.03) and 0.24% (standard deviation, 1.068%) in HCs (p=0.36); between-group difference was significant (p=0.02). No significant PBVC was seen with either group over Months 3-6 or 0-6. Decreased percentage of CD4+ T-cells producing interleukin (IL)-17F over Months 0-6 was significantly correlated with reduced brain volume over Months 0-6 (r=0.51; p=0.02) in RRMS patients.Conclusion: IFN beta-1a SC is associated with reduced brain volume over the first 3 months of treatment, but not over 3-6 months, an effect consistent with treatment-induced pseudoatrophy. Correlation between decreased percentage of CD4+ T-cells producing inflammatory IL-17F and volume reduction is supportive of an early anti-inflammatory therapeutic effect of IFN beta-1a SC.Study supported by: EMD Serono, Inc., Rockland, MA, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc, New York, USA. Disclosure: Dr. Dwyer has received personal compensation for activities with EMD Serono and Claret. Dr. Zivadinov has received personal compensation for activities with Teva, Biogen Idec, EMD Serono, Novartis, Claret and Sanofi-Genzyme. Dr. Zivadinov has received research support from Biogen Idec, Teva Pharmaceuticals, Sanofi-Genzyme, Novartis and EMD Serono. Dr. Tao has received personal compensation for activities with EMD Serono. Dr. Zhang has received personal compensation for activities with EMD Serono. Dr. Kennedy has nothing to disclose. Dr. Bergsland has nothing to disclose. Dr. Ramasamy has nothing to disclose. Dr. Durfee has nothing to disclose. Dr. Hojnacki has received personal compensation for activities with EMD Serono. Dr. Weinstock-Guttman has received personal compensation for activities with Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer, Novartis, Genzyme, Sanofi-Aventis Pharmaceuticals, Inc., Mylan, and Acorda Therapeutics. Dr. Weinstock-Guttman has received research support from Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer Inc, Novartis, Acorda, ITN, Questcor, Shire, Genzyme, Sanofi-Aventis Pharmaceuticals, Inc., National Multiple Sclerosis Society, the National Institutes of Health and Aspreva-Roche. Dr. Hayward has received personal compensation for activities with EMD Serono as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. Dr. Markovic has received personal compensation for activities with EMD Serono. Dr. Markovic has received research support from EMD Serono, Biogen Idec., and Genzyme Corp." @default.
• W1499695412 created "2016-06-24" @default.
• W1499695412 creator A5006651636 @default.
• W1499695412 creator A5010771032 @default.
• W1499695412 creator A5017137555 @default.
• W1499695412 creator A5034859462 @default.
• W1499695412 creator A5041234325 @default.
• W1499695412 creator A5055648634 @default.
• W1499695412 creator A5072623319 @default.
• W1499695412 creator A5073733099 @default.
• W1499695412 creator A5075596287 @default.
• W1499695412 creator A5079130521 @default.
• W1499695412 creator A5080347094 @default.
• W1499695412 creator A5088215267 @default.
• W1499695412 creator A5089267785 @default.
• W1499695412 date "2014-04-08" @default.
• W1499695412 modified "2023-10-17" @default.
• W1499695412 title "Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146)" @default.
• W1499695412 hasPublicationYear "2014" @default.
• W1499695412 type Work @default.
• W1499695412 sameAs 1499695412 @default.
• W1499695412 citedByCount "0" @default.
• W1499695412 crossrefType "journal-article" @default.
• W1499695412 hasAuthorship W1499695412A5006651636 @default.
• W1499695412 hasAuthorship W1499695412A5010771032 @default.
• W1499695412 hasAuthorship W1499695412A5017137555 @default.
• W1499695412 hasAuthorship W1499695412A5034859462 @default.
• W1499695412 hasAuthorship W1499695412A5041234325 @default.
• W1499695412 hasAuthorship W1499695412A5055648634 @default.
• W1499695412 hasAuthorship W1499695412A5072623319 @default.
• W1499695412 hasAuthorship W1499695412A5073733099 @default.
• W1499695412 hasAuthorship W1499695412A5075596287 @default.
• W1499695412 hasAuthorship W1499695412A5079130521 @default.
• W1499695412 hasAuthorship W1499695412A5080347094 @default.
• W1499695412 hasAuthorship W1499695412A5088215267 @default.
• W1499695412 hasAuthorship W1499695412A5089267785 @default.
• W1499695412 hasConcept C126322002 @default.
• W1499695412 hasConcept C126838900 @default.
• W1499695412 hasConcept C12868164 @default.
• W1499695412 hasConcept C143409427 @default.
• W1499695412 hasConcept C203014093 @default.
• W1499695412 hasConcept C206041023 @default.
• W1499695412 hasConcept C2780640218 @default.
• W1499695412 hasConcept C2781172350 @default.
• W1499695412 hasConcept C2908698914 @default.
• W1499695412 hasConcept C2994247566 @default.
• W1499695412 hasConcept C3020694758 @default.
• W1499695412 hasConcept C65835030 @default.
• W1499695412 hasConcept C71924100 @default.
• W1499695412 hasConcept C90924648 @default.
• W1499695412 hasConceptScore W1499695412C126322002 @default.
• W1499695412 hasConceptScore W1499695412C126838900 @default.
• W1499695412 hasConceptScore W1499695412C12868164 @default.
• W1499695412 hasConceptScore W1499695412C143409427 @default.
• W1499695412 hasConceptScore W1499695412C203014093 @default.
• W1499695412 hasConceptScore W1499695412C206041023 @default.
• W1499695412 hasConceptScore W1499695412C2780640218 @default.
• W1499695412 hasConceptScore W1499695412C2781172350 @default.
• W1499695412 hasConceptScore W1499695412C2908698914 @default.
• W1499695412 hasConceptScore W1499695412C2994247566 @default.
• W1499695412 hasConceptScore W1499695412C3020694758 @default.
• W1499695412 hasConceptScore W1499695412C65835030 @default.
• W1499695412 hasConceptScore W1499695412C71924100 @default.
• W1499695412 hasConceptScore W1499695412C90924648 @default.
• W1499695412 hasOpenAccess W1499695412 @default.
• W1499695412 hasVolume "82" @default.
• W1499695412 isParatext "false" @default.
• W1499695412 isRetracted "false" @default.
• W1499695412 magId "1499695412" @default.
• W1499695412 workType "article" @default.